Here comes another anti-Covid vaccine. Johnson & Johnson serum has been approved by the FDA and now it will be examined by the EMA. The novelty is not insignificant. Not only because after Pfizer-BionTech, Moderna and Astrazeneca, we will have another weapon at our disposal to combat the coronavirus emergency, but also because, compared to the others already in circulation, the vaccine produced by Janssen, the group's pharmaceutical company, has a key feature: it is single-dose. Governments and Regions will therefore not need to program two different administrations or keep the doses necessary for the booster in a safe. You can do it all in one go.
According to the latest tests released this week by the FDA, whey is 85 percent effective at preventing severe disease. The overall effectiveness rate is instead at 72% in the USA and 56% in South Africa. The vaccine is based on viral vectors that use adenoviruses that cannot replicate and which carry the Covid genes into cells. Another important feature: unlike those produced by Pfizer and Moderna, it can be stored at normal refrigeration temperatures for at least three months.
The US Food and Drug Administration gave the emergency green light for Johnson & Johnson's single-dose vaccine on Saturday. Then it will be up to the EMA.
The vaccine “I think is in the pipeline. The decision of the European Medicines Agency Ema could arrive in the first 15 days of March” on approval. This was announced by Armando Genazzani, the Italian representative in the Chmp technical committee of the EMA, to the microphones of '24Mattino' on Radio24. Italy, through the European Union, has already booked 26 million doses.
(Last update: 09.35 pm on 28 February).
